{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:13:58Z","timestamp":1785251638473,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11845-025-03945-0","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:45:45Z","timestamp":1744188345000},"page":"899-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination therapy with vitamin E and ertugliflozin in patients with\u00a0non-alcoholic fatty liver disease and type 2 diabetes mellitus: a randomized clinical trial"],"prefix":"10.1007","volume":"194","author":[{"given":"Adil","family":"Khaliq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-0414","authenticated-orcid":false,"given":"Haroon","family":"Badshah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"4","key":"3945_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL and others (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44(4):865\u2013873","journal-title":"Hepatology"},{"issue":"9","key":"3945_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/apt.17723","volume":"58","author":"G Feng","year":"2023","unstructured":"Feng G, Fouad Y, Zheng MH (2023) Letter: detecting unreported alcohol consumption in patients with NAFLD-Standardisation is urgent. Aliment Pharmacol Ther 58(9):967\u2013968","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"3945_CR3","first-page":"e0286586","volume":"18","author":"C Chacon","year":"2023","unstructured":"Chacon C, Arteaga I, Martinez-Escude A and others (2023) Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol PLoS One 18(10):e0286586","journal-title":"The LiverKids: Study protocol PLoS One"},{"issue":"2","key":"3945_CR4","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.jhep.2023.09.035","volume":"80","author":"L He","year":"2023","unstructured":"He L, Zheng W, Qiu K and others (2023) Changing from NAFLD to MASLD: the new definition can more accurately identify individuals at higher risk for diabetes. J Hepatol. 80(2):e85\u2013e87","journal-title":"J Hepatol."},{"issue":"11","key":"3945_CR5","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/hep4.2069","volume":"6","author":"T Arai","year":"2022","unstructured":"Arai T, Atsukawa M, Tsubota A and others (2022) Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun 6(11):3073\u20133082","journal-title":"Hepatol Commun"},{"issue":"1","key":"3945_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/TP.0000000000002480","volume":"103","author":"I Pierantonelli","year":"2019","unstructured":"Pierantonelli I, Svegliati-Baroni G (2019) Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplant 103(1):e1\u20133","journal-title":"Transplantation"},{"key":"3945_CR7","doi-asserted-by":"crossref","unstructured":"Deng G, Li J, Huang M et al (2023) Erchen decoction alleviates the progression of NAFLD by inhibiting lipid accumulation and iron overload through Caveolin-1 signaling. J Ethnopharmacol 319:117320","DOI":"10.1016\/j.jep.2023.117320"},{"issue":"5","key":"3945_CR8","first-page":"e14974","volume":"13","author":"C Das","year":"2021","unstructured":"Das C, Tripathy D, Swain S and others (2021) Effect of dapagliflozin on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a single-center survey. Cureus 13(5):e14974","journal-title":"Cureus"},{"issue":"37","key":"3945_CR9","doi-asserted-by":"publisher","first-page":"eadh0831","DOI":"10.1126\/sciadv.adh0831","volume":"9","author":"E Boslem","year":"2023","unstructured":"Boslem E, Reibe S, Carlessi R and others (2023) Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC. Sci Adv 9(37):eadh0831","journal-title":"Sci Adv"},{"issue":"6","key":"3945_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/medicina59061136","volume":"59","author":"IC Bica","year":"2023","unstructured":"Bica IC, Stoica RA, Salmen T et al (2023) The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: a systematic review of randomized controlled trials. Med 59(6):1136","journal-title":"Medicina"},{"key":"3945_CR11","doi-asserted-by":"crossref","unstructured":"Cinti F, Moffa S, Impronta F et al (2017) Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Dev Ther 11:2905\u20132919","DOI":"10.2147\/DDDT.S114932"},{"key":"3945_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F and others (2021) Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Therapy 12:843\u2013861","journal-title":"Diabetes Therapy"},{"issue":"45","key":"3945_CR13","doi-asserted-by":"publisher","first-page":"e40356","DOI":"10.1097\/MD.0000000000040356","volume":"103","author":"A Khaliq","year":"2024","unstructured":"Khaliq A, Badshah H, Shah Y and others (2024) The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: a randomized controlled trial. Medicine 103(45):e40356","journal-title":"Medicine"},{"issue":"11","key":"3945_CR14","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1002\/ptr.7279","volume":"35","author":"MB Majnooni","year":"2021","unstructured":"Majnooni MB, Ataee M, Bahrami G and others (2021) The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: a randomized clinical trial. Phytother Res 35(11):6324\u20136334","journal-title":"Phytother Res"},{"issue":"12","key":"3945_CR15","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1111\/jgh.16723","volume":"39","author":"NMZ Chee","year":"2024","unstructured":"Chee NMZ, Sinnanaidu RP, Chan WK (2024) Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis. J Gastroenterol Hepatol 39(12):2545\u20132554","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3945_CR16","first-page":"3932","volume":"8","author":"T Handayani","year":"2024","unstructured":"Handayani T, Prijanti AR (2024) The effects of vitamin E administration in non-alcoholic fatty liver disease. Bioscientia Medicina: J Biomed Translational Res 8(1):3932\u20133939","journal-title":"Bioscientia Medicina: J Biomed Translational Res"},{"issue":"3","key":"3945_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/nu17030408","volume":"17","author":"K Szewczyk","year":"2025","unstructured":"Szewczyk K, Bry\u015b J, Brzezi\u0144ska R and others (2025) Nutritional status of vitamin E and its association with metabolic health in adults. Nutrients 17(3):408","journal-title":"Nutrients"},{"key":"3945_CR18","doi-asserted-by":"publisher","first-page":"1216412","DOI":"10.3389\/fmed.2023.1216412","volume":"10","author":"SW Dang","year":"2023","unstructured":"Dang SW, Gao L, Li YJ and others (2023) Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy. Front Med (Lausanne) 10:1216412","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3945_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/ijdt.ijdt_10_24","volume":"3","author":"B Sinha","year":"2024","unstructured":"Sinha B, Ghosal S, Datta D (2024) Comparative efficacy of saroglitazar and pioglitazone in nonalcoholic fatty liver disease patients: a Bayesian network meta-analysis. Int J Diab Technol 3(1):7\u201314","journal-title":"Int J Diab Technol"},{"issue":"7","key":"3945_CR20","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1111\/dom.15622","volume":"26","author":"ML Chang","year":"2024","unstructured":"Chang ML, Tai J, Cheng JS and others (2024) Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: a 3-year prospective cohort study. Diabetes Obes Metab 26(7):2969\u20132978","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"3945_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW and others (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"5","key":"3945_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1586\/17474124.2015.1007955","volume":"9","author":"S Ballestri","year":"2015","unstructured":"Ballestri S, Romagnoli D, Nascimbeni F and others (2015) Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 9(5):603\u2013627","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3945_CR23","doi-asserted-by":"crossref","unstructured":"Khaliq A, Badshah H, Shah Y et al. (2024) The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin on patients of non-alcoholic fatty liver disease in type 2 diabetes mellitus. 59(16):1931","DOI":"10.21203\/rs.3.rs-3982234\/v1"},{"issue":"1","key":"3945_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dom.14559","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Inzucchi SE, Mattheus M and others (2022) Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab 24(1):135\u2013141","journal-title":"Diabetes Obes Metab"},{"key":"3945_CR25","doi-asserted-by":"crossref","unstructured":"Perumpail BJ, Li AA, John N et al (2018) The role of vitamin E in the treatment of NAFLD. Dis 6(4):86","DOI":"10.3390\/diseases6040086"},{"key":"3945_CR26","doi-asserted-by":"crossref","unstructured":"Mishra P, Younossi ZM (2007) Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Off J Am Coll Gastroenterol ACG 102(12):2716\u20132717","DOI":"10.1111\/j.1572-0241.2007.01520.x"},{"key":"3945_CR27","doi-asserted-by":"crossref","unstructured":"Okekunle AP, Youn J, Song S et al. (2023) Predicted pro-inflammatory hs-CRP score and non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 11:goad059.","DOI":"10.1093\/gastro\/goad059"},{"issue":"12","key":"3945_CR28","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.21037\/qims.2019.08.03","volume":"9","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Zhang Q, Wu W and others (2019) Hepatic steatosis assessment using ultrasound homodyned-K parametric imaging: the effects of estimators. Quant Imaging Med Surg 9(12):1932\u20131947","journal-title":"Quant Imaging Med Surg"},{"key":"3945_CR29","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.2147\/DMSO.S430740","volume":"16","author":"NM Alorfi","year":"2023","unstructured":"Alorfi NM, Ashour AM (2023) The impact of intermittent fasting on non-alcoholic fatty liver disease in older adults: a review of clinicaltrials.gov registry. Diabetes Metab Syndr Obes 16:3115\u20133121","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"Supplement_1","key":"3945_CR30","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.2337\/dc25-S017","volume":"48","author":"NA ElSayed","year":"2025","unstructured":"ElSayed NA, McCoy RG, Aleppo G et al (2025) 17 Diabetes advocacy: standards of care in diabetes\u20142025. Diabetes Care 48(Supplement_1):S335\u2013S336","journal-title":"Diabetes Care"},{"issue":"3","key":"3945_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/dom.14271","volume":"23","author":"T Danne","year":"2021","unstructured":"Danne T, Edelman S, Frias JP and others (2021) Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index >\/= 27 kg\/m(2). Diabetes Obes Metab 23(3):854\u2013860","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"3945_CR32","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1002\/fsn3.3549","volume":"11","author":"M Taghdir","year":"2023","unstructured":"Taghdir M, Salehi A, Parastouei K and others (2023) Relationship between diet quality and nonalcoholic fatty liver disease predictor indices in Iranian patients with metabolic syndrome: a cross-sectional study. Food Sci Nutr 11(10):6133\u20136139","journal-title":"Food Sci Nutr"},{"issue":"7621","key":"3945_CR33","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bmj.39339.610000.BE","volume":"335","author":"MD Goodyear","year":"2007","unstructured":"Goodyear MD, Krleza-Jeric K, Lemmens T (2007) The declaration of Helsinki. Br Med J Publ Group 335(7621):624\u2013625","journal-title":"Br Med J Publ Group"},{"issue":"1","key":"3945_CR34","first-page":"e1913","volume":"7","author":"Y Deng","year":"2023","unstructured":"Deng Y, Huang J, Wong MCS (2023) Associations of non-alcoholic fatty liver disease and cirrhosis with liver cancer in European and East Asian populations: a Mendelian randomization study. Cancer Rep (Hoboken) 7(1):e1913","journal-title":"Cancer Rep (Hoboken)"},{"issue":"7","key":"3945_CR35","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.3390\/ijms26072959","volume":"26","author":"JE Mejia-Guzman","year":"2025","unstructured":"Mejia-Guzman JE, Belmont-Hernandez RA, Chavez-Tapia NC et al (2025) Metabolic-dysfunction-associated steatotic liver disease: molecular mechanisms, clinical implications, and emerging therapeutic strategies. \u00a0Int J Mol Sci 26(7):2959","journal-title":"\u00a0Int J Mol Sci"},{"issue":"11","key":"3945_CR36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s11883-023-01158-3","volume":"25","author":"S Pourteymour","year":"2023","unstructured":"Pourteymour S, Drevon CA, Dalen KT et al (2023) Mechanisms behind NAFLD: a system genetics perspective. Curr Atheroscler Rep 25(11):869\u2013878","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"3945_CR37","doi-asserted-by":"publisher","first-page":"101449","DOI":"10.1016\/j.jceh.2024.101449","volume":"14","author":"F Tavaglione","year":"2024","unstructured":"Tavaglione F, Loomba R (2024) Emerging combination of saroglitazar and vitamin E for the treatment of NAFLD and NASH. J Clin Exp Hepatol 14(5):101449","journal-title":"J Clin Exp Hepatol"},{"key":"3945_CR38","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40262-020-00875-1","volume":"59","author":"DJ Fediuk","year":"2020","unstructured":"Fediuk DJ, Nucci G, Dawra VK and others (2020) Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor. Clin Pharmacokinet 59:949\u2013965","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3945_CR39","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/dom.14385","volume":"23","author":"I Lingvay","year":"2021","unstructured":"Lingvay I, Greenberg M, Gallo S and others (2021) Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: a VERTIS CV substudy. Diabetes Obes Metab 23(7):1640\u20131651","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3945_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/ijms24010158","volume":"24","author":"JY Chen","year":"2022","unstructured":"Chen JY, Chua D, Lim CO et al (2022) Lessons on drug development: a literature review of challenges faced in nonalcoholic fatty liver disease (NAFLD) clinical trials. Int J Mol Sci 24(1):158","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3945_CR41","first-page":"e31404","volume":"14","author":"M Totade","year":"2022","unstructured":"Totade M, Gaidhane SA (2022) Role of ertugliflozin in the management of diabetes mellitus. Cureus 14(11):e31404","journal-title":"Cureus"},{"key":"3945_CR42","doi-asserted-by":"publisher","unstructured":"Marrs JC, Anderson SL (2020) Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs Context 9. https:\/\/doi.org\/10.7573\/dic.2020-7-4","DOI":"10.7573\/dic.2020-7-4"},{"issue":"10","key":"3945_CR43","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/nu10101383","volume":"10","author":"Z Song","year":"2018","unstructured":"Song Z, Xiaoli AM, Yang F (2018) Regulation and metabolic significance of de novo lipogenesis in adipose tissues. Nutrients 10(10):1383","journal-title":"Nutrients"},{"key":"3945_CR44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s13300-019-0566-x","volume":"10","author":"AM McNeill","year":"2019","unstructured":"McNeill AM, Davies G, Kruger E and others (2019) Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: a systematic literature review and network meta-analysis. Diabetes Therapy 10:473\u2013491","journal-title":"Diabetes Therapy"},{"issue":"8","key":"3945_CR45","first-page":"e43635","volume":"15","author":"IJ Mazhar","year":"2023","unstructured":"Mazhar IJ, Yasir M, Sarfraz S et al (2023) Vitamin E and pioglitazone: a comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease. Cureus 15(8):e43635","journal-title":"Cureus"},{"issue":"6","key":"3945_CR46","first-page":"1397","volume":"11","author":"YQ Chen","year":"2023","unstructured":"Chen YQ (2023) NASH drug development: seeing the light at the end of the tunnel? J Clin Transl Hepatol 11(6):1397\u20131403","journal-title":"J Clin Transl Hepatol"},{"key":"3945_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","volume":"727","author":"M Yokono","year":"2014","unstructured":"Yokono M, Takasu T, Hayashizaki Y and others (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727:66\u201374","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3945_CR48","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41598-024-52482-w","volume":"14","author":"X Qi","year":"2024","unstructured":"Qi X, Guo J, Li Y and others (2024) Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography. Sci Rep 14(1):2592","journal-title":"Sci Rep"},{"key":"3945_CR49","doi-asserted-by":"publisher","unstructured":"Wen H, Deng H, Yang L et al (2024) Vitamin E for people with non\u2010alcoholic fatty liver disease. Cochrane Database Syst Rev (10). https:\/\/doi.org\/10.1002\/14651858.CD015033.pub2","DOI":"10.1002\/14651858.CD015033.pub2"},{"key":"3945_CR50","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F and others (2020) Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther 37:4697\u20134708","journal-title":"Adv Ther"},{"issue":"48","key":"3945_CR51","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.3748\/wjg.v22.i48.10512","volume":"22","author":"CY Zhang","year":"2016","unstructured":"Zhang CY, Yuan WG, He P and others (2016) Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 22(48):10512\u201310522","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3945_CR52","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/iub.1991","volume":"71","author":"M Nagashimada","year":"2019","unstructured":"Nagashimada M, Ota T (2019) Role of vitamin E in nonalcoholic fatty liver disease. IUBMB life 71(4):516\u2013522","journal-title":"IUBMB life"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-03945-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:31:10Z","timestamp":1757161870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-03945-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3945"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-03945-0","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Abdul Wali Khan University Ethical Committee (ethical approval: EC\/AWKUM\/2023\/18.1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, concerning intellectual property. In so doing, we confirm that we have followed the regulations of our institutions concerning intellectual property.We understand that the Corresponding Author is the sole contact for the Editorial process (including the Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions, and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors consent"}}]}}